🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

206+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 206 recruiting trials for “t-cell-prolymphocytic-leukemia

Phase 2RecruitingNCT06738368

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

👨‍⚕️ Ryan D. Cassaday, MD, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Apr 2026View details ↗
Phase 1RecruitingNCT07388563

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

👨‍⚕️ Max J Gordon, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Mar 2026View details ↗
EARLY_Phase 1RecruitingNCT07428707

Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib

👨‍⚕️ Laura S Samples, M.D., National Heart, Lung, and Blood Institute (NHLBI)📍 1 site📅 Started Mar 2026View details ↗
NARecruitingNCT07191119

Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia

👨‍⚕️ Justin E Tanner, PhD, St. Jude Children's Research Hospital📍 1 site📅 Started Mar 2026View details ↗
Phase 1RecruitingNCT06859008

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

👨‍⚕️ Geoffrey Shouse, City of Hope Medical Center📍 1 site📅 Started Feb 2026View details ↗
RecruitingNCT07422337

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

👨‍⚕️ Lauren Appell, MD, Arkansas Children's Research Institute📍 2 sites📅 Started Jan 2026View details ↗
Phase 1RecruitingNCT07078929

Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)

👨‍⚕️ Kanhatai Chiengthong, MD, King Chulalongkorn Memorial Hospital📍 3 sites📅 Started Jan 2026View details ↗
NARecruitingNCT07479927

Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Allogeneic Transplant or Chemotherapy

🏥 Hospital Universitario La Paz📍 1 site📅 Started Dec 2025View details ↗
Phase 1, PHASE2RecruitingNCT07134088

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

👨‍⚕️ MD, Amgen📍 3 sites📅 Started Dec 2025View details ↗
Phase 1, PHASE2RecruitingNCT07052695

Mosunetuzumab for CLL MRD Clearance

👨‍⚕️ Inhye Ahn, MD, Dana-Farber Cancer Institute📍 2 sites📅 Started Nov 2025View details ↗
Phase 1, PHASE2RecruitingNCT07109219

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

🏥 AstraZeneca📍 26 sites📅 Started Nov 2025View details ↗
Phase 3RecruitingNCT07223021

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

👨‍⚕️ Kevin Curran, MD, Memorial Sloan Kettering Cancer Center📍 3 sites📅 Started Oct 2025View details ↗
NARecruitingNCT07327138

Children's Laughter and Fun Yoga as Adjunctive Pain Relief Following Chemotherapy.

👨‍⚕️ Bahaa W Bou Dargham, MD, Beirut Arab University and Hammoud Hospital University Medical Center📍 1 site📅 Started Oct 2025View details ↗
Phase 2RecruitingNCT07221500

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

👨‍⚕️ Nurix Study Director, Nurix Therapeutics, Inc.📍 18 sites📅 Started Oct 2025View details ↗
Phase 1, PHASE2RecruitingNCT07070219

A Study of CTD402 in T-ALL/LBL Patients

🏥 BIOHENG THERAPEUTICS US LLC📍 8 sites📅 Started Oct 2025View details ↗
Phase 1, PHASE2RecruitingNCT05751044

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

👨‍⚕️ Michel Zwaan, Prof. Dr., Princess Máxima Center📍 33 sites📅 Started Oct 2025View details ↗
Enrolling by InvitationNCT07173790

Watch and Wait or Worry and Wait in Indolent Lymphoma

👨‍⚕️ Ja Min Byun, MD, PhD, Seoul National University Hospital📍 4 sites📅 Started Oct 2025View details ↗
Phase 3RecruitingNCT07203352

Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL

👨‍⚕️ Qifa Liu, Nanfang Hospital, Southern Medical University📍 1 site📅 Started Oct 2025View details ↗
EARLY_Phase 1RecruitingNCT07205315

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

🏥 Grit Biotechnology📍 2 sites📅 Started Sep 2025View details ↗
Phase 2RecruitingNCT06561074

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

👨‍⚕️ David McCall, MD, M.D. Anderson Cancer Center📍 1 site📅 Started Sep 2025View details ↗
Page 1 of 11Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →